As a pioneer in messenger RNA (mRNA) therapy and vaccines, the American biotechnology company also announced significant progress in its portfolio of mRNA flux projects.
Mexico City (apro). – American pharmaceutical company Moderna has announced that it is working on a single dose vaccine that combines a booster to combat covid-19 with a booster to fight influenza. It will thereby take another step forward in medical science.
Stéphane Bancel, executive director of the company, stated:
“Today, we announced the first step of the innovative respiratory vaccine program, which is to develop a single-dose vaccine that combines a covid-19 booster and an influenza booster. We have made great progress in recruiting patients to our rare disease program. And, we fully participated in the personalized cancer vaccine trial trials. This is only the beginning of an information-based era in medicine.
In a statement released on Thursday, the manager added: “I am proud of Moderna’s progress in advancing our first-class mRNA production line while responding to the global covid-19 pandemic. Our mRNA platform is a solution to this problem. There are many health issues that face the world, including rare diseases that can affect thousands of people and diseases that impact millions. Personalized medicines can also be used to address individual needs.
The American biotechnology company is a leader in messenger RNA (mRNA), vaccines and therapies. Today, it will announce major improvements in its mRNA flux portfolio portfolio at its fifth annual R&D Day.
Recent updates and developments include:
Covid-19 vaccine development
——Moderna has completed the ongoing submission process of its Covid-19 (mRNA-1273) vaccine biologics license application (BLA).
-A strong antibody response was observed in the third dose/enhanced phase 2 study of mRNA-1273
New development candidate
-Combined vaccine candidate (mRNA-1073) that combines Moderna’s covid-19 vaccine and influenza vaccine candidates.
-Pediatric Joint Vaccine Candidate mRNA-1365 combines Moderna’s RSV vaccine candidate and its hMPV vaccine candidates.
–EBV therapeutic vaccine candidate (mRNA-1195)
——Ultra-rare disease, Crigler-Najjar syndrome type 1 (mRNA-3351); Modern provides free research CN-1 mRNA therapy to the non-profit Institute of Life Changing Medicines (ILCM)
-Phase 1 study of fully registered quadrivalent seasonal influenza vaccine candidate (mRNA-1010)